1h Free Analyst Time
The biologics contract development and manufacturing organization (CDMO) market is forecasted to grow by USD 16.32 billion during 2024-2029, accelerating at a CAGR of 13.7% during the forecast period. The report on the biologics contract development and manufacturing organization (CDMO) market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by availability of cost-efficient resources in emerging markets, strong research and development pipeline of biologics therapeutics, and growing need to focus on core competencies.
The biologics contract development and manufacturing organization (CDMO) market is segmented as below:
By Type
- Mammalian
- Microbial
By Product Type
- Biologics
- Biosimilars
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the biologics contract development and manufacturing organization (CDMO) market covers the following areas:
- Biologics Contract Development And Manufacturing Organization (CDMO) Market sizing
- Biologics Contract Development And Manufacturing Organization (CDMO) Market forecast
- Biologics Contract Development And Manufacturing Organization (CDMO) Market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Analysis
3 Market Landscape
4 Market Sizing
5 Historic Market Size
6 Qualitative Analysis
7 Five Forces Analysis
8 Market Segmentation by Type
9 Market Segmentation by Product Type
10 Customer Landscape
11 Geographic Landscape
12 Drivers, Challenges, and Opportunity/Restraints
13 Competitive Landscape
14 Competitive Analysis
15 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global biologics contract development and manufacturing organization (CDMO) market: 3P Biopharmaceuticals, AbbVie Inc., AGC Biologics, Binex Co. Ltd., Boehringer Ingelheim International GmbH, Bora Pharmaceuticals, Catalent Inc., Evonik Industries AG, FUJIFILM Corp., Grifols SA, J RETTENMAIER and SOHNE GmbH and Co KG, JSR Corp., Kemwell Biopharma Pvt. Ltd., Lonza Group Ltd., Novartis AG, Rentschler Biopharma SE, Samsung Electronics Co. Ltd., Shenzhen Hepalink Pharmaceutical Co. Ltd., Toyobo Co. Ltd., and WuXi Biologics Cayman Inc..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is advent of big data."
According to the report, one of the major drivers for this market is the availability of cost-efficient resources in emerging markets.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 3P Biopharmaceuticals
- AbbVie Inc.
- AGC Biologics
- Binex Co. Ltd.
- Boehringer Ingelheim International GmbH
- Bora Pharmaceuticals
- Catalent Inc.
- Evonik Industries AG
- FUJIFILM Corp.
- Grifols SA
- J RETTENMAIER and SOHNE GmbH and Co KG
- JSR Corp.
- Kemwell Biopharma Pvt. Ltd.
- Lonza Group Ltd.
- Novartis AG
- Rentschler Biopharma SE
- Samsung Electronics Co. Ltd.
- Shenzhen Hepalink Pharmaceutical Co. Ltd.
- Toyobo Co. Ltd.
- WuXi Biologics Cayman Inc.
